http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 11:33:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Alaunos+Therapeutics%2C++++++++++++++++++Filed+by%3A+Price+Adrian/26117199.html si-local-file:///var/storage/secattach/20260305/26117199.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Alaunos+Therapeutics%2C++++++++++++++++++Filed+by%3A+Price+Adrian/26117199.html Thu, 05 Mar 2026 11:33:00 +0000 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Alaunos+Therapeutics%2C++++++++++++++++++Filed+by%3A+Price+Adrian/26117199.html si-local-file:///var/storage/secattach/20260305/26117199.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Alaunos+Therapeutics%2C++++++++++++++++++Filed+by%3A+Price+Adrian/26117199.html Thu, 05 Mar 2026 11:33:00 +0000 O.01405601 TCRT http://www.streetinsider.com/Corporate+News/Alaunos+reports+weight+loss+in+obesity+drug+trial+using+mice/26086471.html <p>Alaunos Therapeutics Inc. (NASDAQ: TCRT) reported that its experimental obesity drug ALN1003 showed dose-related weight loss in two mouse studies using diet-induced obesity models.</p><p>In the first 48-day study, mice treated with ALN1003 showed a peak weight reduction of 12.9% compared to untreated mice on Day 34, with a 10.3% reduction maintained through the end of the study period. The drug also reduced liver weight by 43% and decreased liver injury enzymes including alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase.</p><p>A second 14-day study tested three dose levels and found dose-dependent reductions in food intake and body weight. The highest dose group http://www.streetinsider.com/Corporate+News/Alaunos+reports+weight+loss+in+obesity+drug+trial+using+mice/26086471.html Mon, 02 Mar 2026 06:32:00 +0000 TCRT http://www.streetinsider.com/FDA/Alaunos+reports+weight+loss+in+obesity+drug+trial+using+mice/26086471.html <p>Alaunos Therapeutics Inc. (NASDAQ: TCRT) reported that its experimental obesity drug ALN1003 showed dose-related weight loss in two mouse studies using diet-induced obesity models.</p><p>In the first 48-day study, mice treated with ALN1003 showed a peak weight reduction of 12.9% compared to untreated mice on Day 34, with a 10.3% reduction maintained through the end of the study period. The drug also reduced liver weight by 43% and decreased liver injury enzymes including alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase.</p><p>A second 14-day study tested three dose levels and found dose-dependent reductions in food intake and body weight. The highest dose group http://www.streetinsider.com/FDA/Alaunos+reports+weight+loss+in+obesity+drug+trial+using+mice/26086471.html Mon, 02 Mar 2026 06:32:00 +0000 TCRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+Mar+02/26086431.html si-local-file:///var/storage/secattach/20260302/26086431.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+Mar+02/26086431.html Mon, 02 Mar 2026 06:30:00 +0000 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+Mar+02/26086431.html si-local-file:///var/storage/secattach/20260302/26086431.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+Mar+02/26086431.html Mon, 02 Mar 2026 06:30:00 +0000 O.01405601 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Press+Releases/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html <ul><li><em>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice</em></li><li style="margin-top:5pt; margin-bottom:5pt;"><em>Efforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing</em><br/><br/></li></ul> <p>FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</strong>, an early-stage biotechnology company, today announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating <strong>ALN1003</strong>, the Company’s lead small-molecule drug http://www.streetinsider.com/Globe+Newswire/Alaunos+Therapeutics+Announces+Positive+Preclinical+Proof-of-Concept+Data+for+ALN1003%2C+a+Differentiated+Non-Hormonal+Oral+Treatment+for+Obesity+and+Related+Metabolic+Disorders/26086455.html Mon, 02 Mar 2026 06:30:00 +0000 A.02562977 A.06822034 O.00267623 O.01405601 O.20026344 TCRT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Alaunos+Therapeutics%2C++++++++++++++++++Filed+by%3A+Price+Adrian/26052697.html si-local-file:///var/storage/secattach/20260224/26052697.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Alaunos+Therapeutics%2C++++++++++++++++++Filed+by%3A+Price+Adrian/26052697.html Tue, 24 Feb 2026 16:56:00 +0000 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Alaunos+Therapeutics%2C++++++++++++++++++Filed+by%3A+Price+Adrian/26052697.html si-local-file:///var/storage/secattach/20260224/26052697.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Alaunos+Therapeutics%2C++++++++++++++++++Filed+by%3A+Price+Adrian/26052697.html Tue, 24 Feb 2026 16:56:00 +0000 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Jerman+Michael+Allen/25855766.html si-local-file:///var/storage/secattach/20260115/25855766.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Jerman+Michael+Allen/25855766.html Thu, 15 Jan 2026 16:15:00 +0000 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Jerman+Michael+Allen/25855766.html si-local-file:///var/storage/secattach/20260115/25855766.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Jerman+Michael+Allen/25855766.html Thu, 15 Jan 2026 16:15:00 +0000 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Postma+Robert+W/25855768.html si-local-file:///var/storage/secattach/20260115/25855768.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Postma+Robert+W/25855768.html Thu, 15 Jan 2026 16:15:00 +0000 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Postma+Robert+W/25855768.html si-local-file:///var/storage/secattach/20260115/25855768.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Postma+Robert+W/25855768.html Thu, 15 Jan 2026 16:15:00 +0000 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Vieser+Jaime/25855773.html si-local-file:///var/storage/secattach/20260115/25855773.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+Jan+12++Filed+by%3A+Vieser+Jaime/25855773.html Thu, 15 Jan 2026 16:15:00 +0000 O.01405601 TCRT